Press Releases Year None2021202020192018201720162015201420132012 Jul 27 Regeneron and AstraZeneca to Research, Develop and Commercialize New Small Molecule Medicines for Obesity Jul 20 Japan Becomes First Country to Approve Regeneron Antibody Cocktail (casirivimab and imdevimab) for the Treatment of Mild to Moderate COVID-19 Jul 7 Regeneron to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2021 Jul 1 Regeneron Genetics Center Discovers GPR75 Gene Mutations that Protect Against Obesity Jun 28 Dupixent® (dupilumab) SmPC Updated with Long-term Data Reinforcing Well-established Safety Profile in Adults with Moderate-to-severe Atopic Dermatitis Jun 26 Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis Jun 25 Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma Jun 25 Libtayo® (cemiplimab) Approved by the European Commission for First-Line Treatment of Patients with Advanced Non-small Cell Lung Cancer with ≥50% PD-L1 Expression Jun 22 Regeneron to Participate in Guggenheim Biopharma Strategy Series Jun 16 REGEN-COV™ (casirivimab and imdevimab) Phase 3 RECOVERY Trial Meets Primary Outcome, Improving Survival in Hospitalized COVID-19 Patients Lacking an Immune Response to SARS-CoV-2 Current page 1 Page 2 Page 3 Page 4 Page 5 Next page › Last page »